[8-K] Nephros Inc. Reports Material Event
Nephros, Inc. furnished a press release disclosing its second quarter 2025 financial results and included that press release as Exhibit 99.1 to this Form 8-K. The company explicitly stated the exhibit is furnished, not filed, and therefore is not subject to liability under Section 18 of the Exchange Act nor automatically incorporated by reference into other filings unless expressly stated. The report was signed on behalf of the registrant by the Chief Financial Officer.
Nephros, Inc. ha fornito un comunicato stampa che rende noti i risultati finanziari del secondo trimestre 2025 e ha allegato tale comunicato come Exhibit 99.1 al presente Modulo 8-K. La società ha precisato esplicitamente che l'allegato è fornito, non depositato, e pertanto non è soggetto a responsabilità ai sensi della Sezione 18 del Securities Exchange Act né viene automaticamente incorporato per riferimento in altri documenti, salvo diversa indicazione espressa. Il rapporto è stato firmato per conto del soggetto registrante dal Chief Financial Officer.
Nephros, Inc. facilitó un comunicado de prensa que da a conocer sus resultados financieros del segundo trimestre de 2025 e incluyó dicho comunicado como Exhibit 99.1 en este Formulario 8-K. La compañía declaró explícitamente que el anexo está suministrado, no presentado, por lo que no está sujeto a responsabilidad conforme a la Sección 18 del Exchange Act ni se incorpora automáticamente por referencia en otros documentos salvo que se indique expresamente lo contrario. El informe fue firmado en nombre del registrante por el Chief Financial Officer.
Nephros, Inc.는 2025년 2분기 재무실적을 공시하는 보도자료를 제공했으며, 해당 보도자료를 본 Form 8-K의 Exhibit 99.1로 첨부했습니다. 회사는 해당 첨부문서가 제공된 것이며 제출된 것은 아님을 명확히 밝혔으며, 따라서 이는 Exchange Act의 Section 18에 따른 책임 대상이 아니고, 명시적으로 달리 언급되지 않는 한 다른 제출서류에 의해 자동으로 참조되어 포함되지 않습니다. 보고서는 등록자의 대리로 최고재무책임자(Chief Financial Officer)가 서명했습니다.
Nephros, Inc. a fourni un communiqué de presse divulguant ses résultats financiers du deuxième trimestre 2025 et a inclus ce communiqué en tant que Exhibit 99.1 dans ce Formulaire 8-K. La société a précisé explicitement que la pièce jointe est fournie, non déposée, et n'est donc pas soumise à la responsabilité en vertu de la Section 18 de l'Exchange Act, ni automatiquement incorporée par référence dans d'autres documents sauf indication expresse contraire. Le rapport a été signé au nom du déposant par le Chief Financial Officer.
Nephros, Inc. stellte eine Pressemitteilung zur Offenlegung seiner Finanzergebnisse für das zweite Quartal 2025 zur Verfügung und fügte diese Pressemitteilung als Exhibit 99.1 zu diesem Form 8-K bei. Das Unternehmen machte ausdrücklich deutlich, dass die Anlage bereitgestellt, nicht eingereicht wurde und daher nicht der Haftung nach Section 18 des Exchange Act unterliegt und nicht automatisch durch Verweis in andere Einreichungen aufgenommen wird, sofern dies nicht ausdrücklich angegeben ist. Der Bericht wurde im Namen des Registranten vom Chief Financial Officer unterzeichnet.
- None.
- None.
Insights
Routine earnings disclosure; filing contains no financial figures itself.
The 8-K notifies investors that Nephros has furnished a press release reporting its Q2 2025 results via Exhibit 99.1. The filing itself contains no revenue, profit, or cash-flow figures, so immediate analytical conclusions cannot be drawn from this document alone. Investors and analysts must review the referenced press release for the substantive financial metrics. The company’s clear statement that the exhibit is "furnished, not filed" is a standard disclosure that limits certain legal exposures and clarifies incorporation status for subsequent filings.
Governance procedure followed; disclosure is procedural rather than transformative.
The Form 8-K follows customary practice by furnishing a press release as an exhibit and stating its furnished (not filed) status. That distinction preserves the company’s disclosure control boundaries while ensuring investors have access to the results. Because the filing does not include the underlying financial statements or management commentary, it should be treated as a notification of disclosure rather than a standalone material update.
Nephros, Inc. ha fornito un comunicato stampa che rende noti i risultati finanziari del secondo trimestre 2025 e ha allegato tale comunicato come Exhibit 99.1 al presente Modulo 8-K. La società ha precisato esplicitamente che l'allegato è fornito, non depositato, e pertanto non è soggetto a responsabilità ai sensi della Sezione 18 del Securities Exchange Act né viene automaticamente incorporato per riferimento in altri documenti, salvo diversa indicazione espressa. Il rapporto è stato firmato per conto del soggetto registrante dal Chief Financial Officer.
Nephros, Inc. facilitó un comunicado de prensa que da a conocer sus resultados financieros del segundo trimestre de 2025 e incluyó dicho comunicado como Exhibit 99.1 en este Formulario 8-K. La compañía declaró explícitamente que el anexo está suministrado, no presentado, por lo que no está sujeto a responsabilidad conforme a la Sección 18 del Exchange Act ni se incorpora automáticamente por referencia en otros documentos salvo que se indique expresamente lo contrario. El informe fue firmado en nombre del registrante por el Chief Financial Officer.
Nephros, Inc.는 2025년 2분기 재무실적을 공시하는 보도자료를 제공했으며, 해당 보도자료를 본 Form 8-K의 Exhibit 99.1로 첨부했습니다. 회사는 해당 첨부문서가 제공된 것이며 제출된 것은 아님을 명확히 밝혔으며, 따라서 이는 Exchange Act의 Section 18에 따른 책임 대상이 아니고, 명시적으로 달리 언급되지 않는 한 다른 제출서류에 의해 자동으로 참조되어 포함되지 않습니다. 보고서는 등록자의 대리로 최고재무책임자(Chief Financial Officer)가 서명했습니다.
Nephros, Inc. a fourni un communiqué de presse divulguant ses résultats financiers du deuxième trimestre 2025 et a inclus ce communiqué en tant que Exhibit 99.1 dans ce Formulaire 8-K. La société a précisé explicitement que la pièce jointe est fournie, non déposée, et n'est donc pas soumise à la responsabilité en vertu de la Section 18 de l'Exchange Act, ni automatiquement incorporée par référence dans d'autres documents sauf indication expresse contraire. Le rapport a été signé au nom du déposant par le Chief Financial Officer.
Nephros, Inc. stellte eine Pressemitteilung zur Offenlegung seiner Finanzergebnisse für das zweite Quartal 2025 zur Verfügung und fügte diese Pressemitteilung als Exhibit 99.1 zu diesem Form 8-K bei. Das Unternehmen machte ausdrücklich deutlich, dass die Anlage bereitgestellt, nicht eingereicht wurde und daher nicht der Haftung nach Section 18 des Exchange Act unterliegt und nicht automatisch durch Verweis in andere Einreichungen aufgenommen wird, sofern dies nicht ausdrücklich angegeben ist. Der Bericht wurde im Namen des Registranten vom Chief Financial Officer unterzeichnet.
FAQ
What did Nephros (NEPH) disclose in this 8-K?
Is the press release included in the filing "filed" with the SEC?
Does the 8-K include the actual financial numbers for Q2 2025?
Where can I find the financial details referenced in this 8-K?
Who signed the Form 8-K for Nephros?
